AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
NanoViricides shares surge 10.74% after-hours as company highlights NV-387's broad-spectrum antiviral efficacy at Pharma Partnering Summit 2025.
ByAinvest
Friday, Nov 14, 2025 5:11 pm ET1min read
NanoViricides surged 10.74% in after-hours trading following its announcement to present at the Pharma Partnering Summit 2025, highlighting its Phase II antiviral drug NV-387. The company emphasized NV-387’s broad-spectrum efficacy against viruses like H3N2, RSV, and MPox, noting its unique mechanism to prevent viral escape and potential as a first-line treatment for respiratory infections. The presentation underscored progress in advancing NV-387 toward Phase II trials in the DRC for MPox and its applicability to unmet medical needs in influenza, measles, and smallpox. The event also showcased the company’s platform technology, including pipeline candidates for herpesviruses and HIV, and highlighted NV-387’s market potential exceeding $20 billion. The news reinforced investor confidence in NanoViricides’ innovative antiviral pipeline and strategic partnerships.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet